Hamzah Syed1, Andrea L Jorgensen2, Andrew P Morris2,3. 1. Department of Biostatistics, University of Liverpool, Liverpool, UK. hamzah.syed@liverpool.ac.uk. 2. Department of Biostatistics, University of Liverpool, Liverpool, UK. 3. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Abstract
BACKGROUND: Analysis of genome-wide association studies (GWAS) with "time to event" outcomes have become increasingly popular, predominantly in the context of pharmacogenetics, where the survival endpoint could be death, disease remission or the occurrence of an adverse drug reaction. However, methodology and software that can efficiently handle the scale and complexity of genetic data from GWAS with time to event outcomes has not been extensively developed. RESULTS: SurvivalGWAS_SV is an easy to use software implemented using C# and run on Linux, Mac OS X & Windows operating systems. SurvivalGWAS_SV is able to handle large scale genome-wide data, allowing for imputed genotypes by modelling time to event outcomes under a dosage model. Either a Cox proportional hazards or Weibull regression model is used for analysis. The software can adjust for multiple covariates and incorporate SNP-covariate interaction effects. CONCLUSIONS: We introduce a new console application analysis tool for the analysis of GWAS with time to event outcomes. SurvivalGWAS_SV is compatible with high performance parallel computing clusters, thereby allowing efficient and effective analysis of large scale GWAS datasets, without incurring memory issues. With its particular relevance to pharmacogenetic GWAS, SurvivalGWAS_SV will aid in the identification of genetic biomarkers of patient response to treatment, with the ultimate goal of personalising therapeutic intervention for an array of diseases.
BACKGROUND: Analysis of genome-wide association studies (GWAS) with "time to event" outcomes have become increasingly popular, predominantly in the context of pharmacogenetics, where the survival endpoint could be death, disease remission or the occurrence of an adverse drug reaction. However, methodology and software that can efficiently handle the scale and complexity of genetic data from GWAS with time to event outcomes has not been extensively developed. RESULTS: SurvivalGWAS_SV is an easy to use software implemented using C# and run on Linux, Mac OS X & Windows operating systems. SurvivalGWAS_SV is able to handle large scale genome-wide data, allowing for imputed genotypes by modelling time to event outcomes under a dosage model. Either a Cox proportional hazards or Weibull regression model is used for analysis. The software can adjust for multiple covariates and incorporate SNP-covariate interaction effects. CONCLUSIONS: We introduce a new console application analysis tool for the analysis of GWAS with time to event outcomes. SurvivalGWAS_SV is compatible with high performance parallel computing clusters, thereby allowing efficient and effective analysis of large scale GWAS datasets, without incurring memory issues. With its particular relevance to pharmacogenetic GWAS, SurvivalGWAS_SV will aid in the identification of genetic biomarkers of patient response to treatment, with the ultimate goal of personalising therapeutic intervention for an array of diseases.
Entities:
Keywords:
Cox proportional hazards; Genome-wide association study; Pharmacogenetics; SNP-covariate interaction; Survival analysis; Time to event; Weibull
Authors: Amanda I Phipps; Michael N Passarelli; Andrew T Chan; Tabitha A Harrison; Jihyoun Jeon; Carolyn M Hutter; Sonja I Berndt; Hermann Brenner; Bette J Caan; Peter T Campbell; Jenny Chang-Claude; Stephen J Chanock; Jeremy P Cheadle; Keith R Curtis; David Duggan; David Fisher; Charles S Fuchs; Manish Gala; Edward L Giovannucci; Richard B Hayes; Michael Hoffmeister; Li Hsu; Eric J Jacobs; Lina Jansen; Richard Kaplan; Elisabeth J Kap; Timothy S Maughan; John D Potter; Robert E Schoen; Daniela Seminara; Martha L Slattery; Hannah West; Emily White; Ulrike Peters; Polly A Newcomb Journal: Carcinogenesis Date: 2015-11-19 Impact factor: 4.944
Authors: V Le Morvan; S Litière; A Laroche-Clary; S Ait-Ouferoukh; R Bellott; C Messina; D Cameron; H Bonnefoi; J Robert Journal: Pharmacogenomics J Date: 2014-06-24 Impact factor: 3.550
Authors: J-Y Han; Y-S Lee; E Soon Shin; J-A Hwang; S Nam; S-H Hong; H Young Ghang; J Young Kim; S Jin Yoon; J Soo Lee Journal: Pharmacogenomics J Date: 2013-03-12 Impact factor: 3.550
Authors: David M Altshuler; Richard A Gibbs; Leena Peltonen; David M Altshuler; Richard A Gibbs; Leena Peltonen; Emmanouil Dermitzakis; Stephen F Schaffner; Fuli Yu; Leena Peltonen; Emmanouil Dermitzakis; Penelope E Bonnen; David M Altshuler; Richard A Gibbs; Paul I W de Bakker; Panos Deloukas; Stacey B Gabriel; Rhian Gwilliam; Sarah Hunt; Michael Inouye; Xiaoming Jia; Aarno Palotie; Melissa Parkin; Pamela Whittaker; Fuli Yu; Kyle Chang; Alicia Hawes; Lora R Lewis; Yanru Ren; David Wheeler; Richard A Gibbs; Donna Marie Muzny; Chris Barnes; Katayoon Darvishi; Matthew Hurles; Joshua M Korn; Kati Kristiansson; Charles Lee; Steven A McCarrol; James Nemesh; Emmanouil Dermitzakis; Alon Keinan; Stephen B Montgomery; Samuela Pollack; Alkes L Price; Nicole Soranzo; Penelope E Bonnen; Richard A Gibbs; Claudia Gonzaga-Jauregui; Alon Keinan; Alkes L Price; Fuli Yu; Verneri Anttila; Wendy Brodeur; Mark J Daly; Stephen Leslie; Gil McVean; Loukas Moutsianas; Huy Nguyen; Stephen F Schaffner; Qingrun Zhang; Mohammed J R Ghori; Ralph McGinnis; William McLaren; Samuela Pollack; Alkes L Price; Stephen F Schaffner; Fumihiko Takeuchi; Sharon R Grossman; Ilya Shlyakhter; Elizabeth B Hostetter; Pardis C Sabeti; Clement A Adebamowo; Morris W Foster; Deborah R Gordon; Julio Licinio; Maria Cristina Manca; Patricia A Marshall; Ichiro Matsuda; Duncan Ngare; Vivian Ota Wang; Deepa Reddy; Charles N Rotimi; Charmaine D Royal; Richard R Sharp; Changqing Zeng; Lisa D Brooks; Jean E McEwen Journal: Nature Date: 2010-09-02 Impact factor: 49.962
Authors: A Ray; L Tennakoon; J Keller; J E Sarginson; H S Ryan; G M Murphy; L C Lazzeroni; M H Trivedi; J H Kocsis; C DeBattista; A F Schatzberg Journal: Pharmacogenomics J Date: 2014-12-09 Impact factor: 3.550
Authors: David C Johnson; Niels Weinhold; Jonathan S Mitchell; Bowang Chen; Martin Kaiser; Dil B Begum; Jens Hillengass; Uta Bertsch; Walter A Gregory; David Cairns; Graham H Jackson; Asta Försti; Jolanta Nickel; Per Hoffmann; Markus M Nöethen; Owen W Stephens; Bart Barlogie; Faith E Davis; Kari Hemminki; Hartmut Goldschmidt; Richard S Houlston; Gareth J Morgan Journal: Nat Commun Date: 2016-01-08 Impact factor: 14.919
Authors: Ryan Langdon; Rebecca Richmond; Hannah R Elliott; Tom Dudding; Nabila Kazmi; Chris Penfold; Kate Ingarfield; Karen Ho; Andrew Bretherick; Chris Haley; Yanni Zeng; Rosie M Walker; Michael Pawlita; Tim Waterboer; Tom Gaunt; George Davey Smith; Matthew Suderman; Steve Thomas; Andy Ness; Caroline Relton Journal: Clin Epigenetics Date: 2020-06-29 Impact factor: 6.551
Authors: Jacob J Hughey; Seth D Rhoades; Darwin Y Fu; Lisa Bastarache; Joshua C Denny; Qingxia Chen Journal: BMC Genomics Date: 2019-11-04 Impact factor: 3.969
Authors: Sven E Ojavee; Athanasios Kousathanas; Daniel Trejo Banos; Etienne J Orliac; Marion Patxot; Kristi Läll; Reedik Mägi; Krista Fischer; Zoltan Kutalik; Matthew R Robinson Journal: Nat Commun Date: 2021-04-20 Impact factor: 14.919